Prostate cancer invasion and metastasis: Insights frommining genomic data

Briefings in Functional Genomics

Volumn 12, Issue 5, 2013, Pages 397-410

  Hudson, Bryan D ^a   Kulp, Kristen S ^a   Loots, Gabriela G ^a  

^a LAWRENCE LIVERMORE NATIONAL LABORATORY   (United States)

Author keywords

Biomarkers; Bone metastasis; Metastasis; Microarrays; Prostate cancer; RNA seq

Indexed keywords

BIOLOGICAL MARKER; TRANSCRIPTOME; WNT5A PROTEIN;

ANGIOGENESIS; ARTICLE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER MORTALITY; CANCER RESISTANCE; CANCER SURVIVAL; DATA MINING; DNA MICROARRAY; EXTRAVASATION; GENE EXPRESSION; GENOMICS; HIGH THROUGHPUT SEQUENCING; HUMAN; METASTASIS; NONHUMAN; PROGNOSIS; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; RNA SEQUENCE; TRANSCRIPTOMICS; TUMOR INVASION; TUMOR VASCULARIZATION;

BIOMARKERS; BONE METASTASIS; METASTASIS; MICROARRAYS; PROSTATE CANCER; RNA-SEQ;

DATA MINING; DATABASES, GENETIC; GENOMICS; HUMANS; MALE; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; PROSTATIC NEOPLASMS;

EID: 84884507114     PISSN: 20412649     EISSN: 20412657     Source Type: Journal    
DOI: 10.1093/bfgp/elt021     Document Type: Article

References (165)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CACancerJ Clin 2012;62:10-29.
2. Eccles SA, Welch DR. Metastasis: recent discoveries and novel treatment strategies. Lancet 2007;369:1742-57.
3. Lee RJ, Saylor PJ, Smith MR. Treatment and prevention of bone complications from prostate cancer. Bone 2011;48: 88-95.
4. Jin JK, Dayyani F, Gallick GE. Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer 2011; 128:2545-61.
5. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007;8:341-52.
6. Costa L, Major PP. Effect of bisphosphonates on pain and quality of life in patients with bone metastases. NatClinPract Oncol 2009;6:163-74.
7. Fidler IJ, Poste G. The "seed and soil" hypothesis revisited. Lancet Oncol 2008;9:808.
8. Roy NC, Altermann E, Park ZA, et al. A comparison of analog and Next-Generation transcriptomic tools for mammalian studies. Brief Funct Genomics 2011;10:135-50.
9. Polyak K, Haviv I, Campbell IG. Co-evolution of tumor cells and their microenvironment. Trends Genet 2009;25: 30-8.
10. Clarke NW, Hart CA, Brown MD. Molecular mechanisms of metastasis in prostate cancer. Asian J Androl 2009;11: 57-67.
11. Bueno R, Loughlin KR, Powell MH, et al. A diagnostic test for prostate cancer from gene expression profiling data. JUrol 2004;171:903-6.
12. Chaib H, Cockrell EK, Rubin MA, etal. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia 2001;3:43-52.
13. Ernst T, Hergenhahn M, Kenzelmann M, et al. Decrease and gain of gene expression are equally discriminatory markers for prostate carcinoma: a gene expression analysis on total and microdissected prostate tissue. AmJ Pathol 2002; 160:2169-80.
14. Ishiguro H, Uemura H, Fujinami K, et al. 55 kDa nuclear matrix protein (nmt55) mRNA is expressed in human prostate cancer tissue and is associated with the androgen receptor. IntJCancer 2003;105:26-32.
15. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad SciUSA 2004;101:811-6.
16. Latil A, Bieche I, Chene L, et al. Gene expression profiling in clinically localized prostate cancer: a four-gene expression model predicts clinical behavior. Clin Cancer Res 2003;9: 5477-85.
17. Lichtinghagen R, Musholt PB, Stephan C, et al. mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. Anticancer Res 2003;23:2617-24.
18. Luo J, Isaacs WB, Trent JM, et al. Looking beyond morphology: cancer gene expression profiling using DNA microarrays. Cancer Invest 2003;21:937-49.
19. Luo JH, Yu YP. Genetic factors underlying prostate cancer. Expert RevMolMed 2003;5:1-26.
20. Magee JA, Araki T, Patil S, et al. Expression profiling reveals hepsin overexpression in prostate cancer. Cancer Res 2001; 61:5692-6.
21. Rossi S, Graner E, Febbo P, et al. Fatty acid synthase expression defines distinct molecular signatures in prostate cancer. Mol Cancer Res 2003;1:707-15.
22. Welsh JB, Sapinoso LM, Su AI, et al. Analysis of gene expression identifies candidate markers and pharmacological targets in prostate cancer. Cancer Res 2001;61:5974-8.
23. Dhanasekaran SM, Barrette TR, Ghosh D, etal. Delineation of prognostic biomarkers in prostate cancer. Nature 2001; 412:822-6.
24. Thelen P, Burfeind P, Grzmil M, et al. cDNA microarray analysis with amplified RNA after isolation of intact cellular RNA from neoplastic and non-neoplastic prostate tissue separated by laser microdissections. Int J Oncol 2004;24: 1085-92.
25. Qian DZ, Huang CY, O'Brien CA, et al. Prostate cancerassociated gene expression alterations determined from needle biopsies. ClinCancer Res 2009;15:3135-42.
26. Risk MC, Knudsen BS, Coleman I, et al. Differential gene expression in benign prostate epithelium of men with and without prostate cancer: evidence for a prostate cancer field effect. Clin Cancer Res 2010;16:5414-23.
27. Nonn L, Vaishnav A, Gallagher L, et al. mRNA and micro- RNA expression analysis in laser-capture microdissected prostate biopsies: valuable tool for risk assessment and prevention trials. ExpMol Pathol 2010;88:45-51.
28. Yoshida E, Tsuchiya K, Sugiki M, et al. Modulation of the receptor for urokinase-type plasminogen activator in macrophage-like U937 cells by inflammatory mediators. Inflammation 1996;20:319-26.
29. Kelly P, Stemmle LN, Madden JF, et al. A role for the G12 family of heterotrimeric G proteins in prostate cancer invasion. J BiolChem 2006;281:26483-90.
30. Li Y, Cozzi PJ. MUC1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets 2007;7: 259-71.
31. Papadopoulos I, Sivridis E, Giatromanolaki A, et al. Tumor angiogenesis is associated with MUC1 overexpression and loss of prostate-specific antigen expression in prostate cancer. Clin Cancer Res 2001;7:1533-8.
32. Cozzi PJ, Wang J, Delprado W, et al. MUC1, MUC2, MUC4, MUC5AC and MUC6 expression in the progression of prostate cancer. Clin ExpMetastasis 2005;22:565-73.
33. Li Y, Sarkar FH. Down-regulation of invasion and angiogenesis- related genes identified by cDNA microarray analysis of PC3 prostate cancer cells treated with genistein. Cancer Lett 2002;186:157-64.
34. Zhang S, Zhau HE, Osunkoya AO, et al. Vascular endothelial growth factor regulates myeloid cell leukemia-1 expression through neuropilin-1-dependent activation of c-MET signaling in human prostate cancer cells. Mol Cancer 2010;9:9.
35. Kirschmann DA, Seftor EA, Fong SF, et al. A molecular role for lysyl oxidase in breast cancer invasion. Cancer Res 2002; 62:4478-83.
36. Attiga FA, Fernandez PM, Weeraratna AT, et al. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res 2000;60:4629-37.
37. Sfiligoi C, de Luca A, Cascone I, et al. Angiopoietin-2 expression in breast cancer correlates with lymph node invasion and short survival. IntJCancer 2003;103:466-74.
38. Tilki D, Irmak S, Oliveira-Ferrer L, et al. CEA-related cell adhesion molecule-1 is involved in angiogenic switch in prostate cancer. Oncogene 2006;25:4965-74.
39. Fuchs B, Mahlum E, Halder C, et al. High expression of tumor endothelial marker 7 is associated with metastasis and poor survival of patients with osteogenic sarcoma. Gene 2007;399:137-43.
40. Halder C, Ossendorf C, Maran A, et al. Preferential expression of the secreted and membrane forms of tumor endothelial marker 7 transcripts in osteosarcoma. Anticancer Res 2009;29:4317-22.
41. Strawbridge RJ, Nister M, Brismar K, et al. MUC1 as a putative prognostic marker for prostate cancer. Biomark Insights 2008;3:303-15.
42. Strawbridge RJ, Nister M, Brismar K, et al. Influence of MUC1 genetic variation on prostate cancer risk and survival. EurJ Hum Genet 2008;16:1521-5.
43. Roy LD, Sahraei M, Subramani DB, et al. MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition. Oncogene 2011;30:1449-59.
44. Li Y, Cozzi PJ, Russell PJ. Promising tumor-associated antigens for future prostate cancer therapy. Med Res Rev 2010; 30:67-101.
45. Morrissey C, True LD, Roudier MP, et al. Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin ExpMetastasis 2008;25:377-88.
46. Morrissey C, Dowell A, Koreckij TD, et al. Inhibition of angiopoietin-2 in LuCaP 23.1 prostate cancer tumors decreases tumor growth and viability. Prostate 2010;70: 1799-808.
47. Balacescu L, Balacescu O, Crisan N, et al. Identifying molecular features for prostate cancer with Gleason 7 based on microarray gene expression profiles. RomJMorphol Embryol 2011;52:1195-202.
48. Galbiati F, Volonte D, Brown AM, et al. Caveolin-1 expression inhibits Wnt/beta-catenin/Lef-1 signaling by recruiting beta-catenin to caveolae membrane domains. J Biol Chem 2000;275:23368-77.
49. Tsujimoto Y, Ikegaki N, Croce CM. Characterization of the protein product of bcl-2, the gene involved in human follicular lymphoma. Oncogene 1987;2:3-7.
50. Wlazlinski A, Engers R, Hoffmann MJ, et al. Downregulation of several fibulin genes in prostate cancer. Prostate 2007;67:1770-80.
51. Lin DW, Coleman IM, Hawley S, et al. Influence of surgical manipulation on prostate gene expression: implications for molecular correlates of treatment effects and disease prognosis. JClin Oncol 2006;24:3763-70.
52. Chay CH, Cooper CR, Gendernalik JD, et al. A functional thrombin receptor (PAR1) is expressed on bone-derived prostate cancer cell lines. Urology 2002;60:760-5.
53. Luo JH, Yu YP, Cieply K, et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002;33:25-35.
54. Lee WH, Morton RA, Epstein JI, et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA 1994;91:11733-7.
55. Srikantan V, Valladares M, Rhim JS, et al. HEPSIN inhibits cell growth/invasion in prostate cancer cells. Cancer Res 2002;62:6812-6.
56. Li Y, Wang L, Zhang M, et al. LEF1 in androgenindependent prostate cancer: regulation of androgen receptor expression, prostate cancer growth, and invasion. Cancer Res 2009;69:3332-8.
57. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. ProcNatl Acad SciUSA 2008;105:2105-10.
58. Becker-Santos DD, Guo Y, Ghaffari M, et al. Integrinlinked kinase as a target for ERG-mediated invasive properties in prostate cancer models. Carcinogenesis 2012;33: 2558-67.
59. Li W, Cagle PT, Botero RC, et al. Significance of overexpression of alpha methylacyl-coenzyme A racemase in hepatocellular carcinoma. J Exp Clin Cancer Res 2008;27:2.
60. Gravina GL, Ranieri G, Muzi P, et al. Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. Oncol Rep 2013;29: 1189-95.
61. Dakhova O, Ozen M, Creighton CJ, et al. Global gene expression analysis of reactive stroma in prostate cancer. ClinCancer Res 2009;15:3979-89.
62. Shukla CJ, Pennington CJ, Riddick AC, et al. Laser-capture microdissection in prostate cancer research: establishment and validation of a powerful tool for the assessment of tumour-stroma interactions. BJUInt 2008;101:765-74.
63. Gregg JL, Brown KE, Mintz EM, et al. Analysis of gene expression in prostate cancer epithelial and interstitial stromal cells using laser capture microdissection. BMC Cancer 2010;10:165.
64. Nakatsuka S, Oji Y, Horiuchi T, et al. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol 2006;19:804-14.
65. Devilard E, Bladou F, Ramuz O, et al. FGFR1 and WT1 are markers of human prostate cancer progression. BMC Cancer 2006;6:272.
66. Ostergaard M, Olesen LH, Hasle H, et al. WT1 gene expression: an excellent tool for monitoring minimal residual disease in 70% of acute myeloid leukaemia patients - results from a single-centre study. BrJHaematol 2004;125:590-600.
67. Miyoshi Y, Ando A, Egawa C, et al. High expression of Wilms' tumor suppressor gene predicts poor prognosis in breast cancer patients. Clin Cancer Res 2002;8:1167-71.
68. Silberstein GB, Van Horn K, Strickland P, et al. Altered expression of the WT1 wilms tumor suppressor gene in human breast cancer. ProcNatlAcad SciUSA 1997;94:8132-7.
69. Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, et al. WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study. BMCCancer 2006;6:90.
70. Foster MR, Johnson JE, Olson SJ, et al. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol LabMed 2001;125:1316-20.
71. Brett A, Pandey S, Fraizer G. The Wilms' tumor gene (WT1) regulates E-cadherin expression and migration of prostate cancer cells. Mol Cancer 2013;12:3.
72. Koukourakis MI, Giatromanolaki A, Brekken RA, et al. Enhanced expression of SPARC/osteonectin in the tumor-associated stroma of non-small cell lung cancer is correlated with markers of hypoxia/acidity and with poor prognosis of patients. Cancer Res 2003;63:5376-80.
73. Sato N, Fukushima N, Maehara N, et al. SPARC/osteonectin is a frequent target for aberrant methylation in pancreatic adenocarcinoma and a mediator of tumor-stromal interactions. Oncogene 2003;22:5021-30.
74. Levin JZ, Berger MF, Adiconis X, et al. Targeted next-generation sequencing of a cancer transcriptome enhances detection of sequence variants and novel fusion transcripts. Genome Biol 2009;10:R115.
75. Berger MF, Levin JZ, Vijayendran K, et al. Integrative analysis of the melanoma transcriptome. Genome Res 2010;20: 413-27.
76. Prensner JR, Iyer MK, Balbin OA, et al. Transcriptome sequencing across a prostate cancer cohort identifies PCAT-1, an unannotated lincRNA implicated in disease progression. Nat Biotechnol 2011;29:742-9.
77. Maher CA, Kumar-Sinha C, Cao X, et al. Transcriptome sequencing to detect gene fusions in cancer. Nature 2009; 458:97-101.
78. Pflueger D, Rickman DS, Sboner A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009;11:804-11.
79. Pflueger D, Terry S, Sboner A, et al. Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing. Genome Res 2011;21:56-67.
80. Jinawath N, Vasoontara C, Jinawath A, et al. Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma. PLoS One 2010;5:e11198.
81. Palanisamy N, Ateeq B, Kalyana-Sundaram S, et al. Rearrangements of the RAF kinase pathway in prostate cancer, gastric cancer and melanoma. Nat Med 2010;16: 793-8.
82. Beltran H, Yelensky R, Frampton GM, etal. Targeted nextgeneration sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity. Eur Urol 2013;63:920-6.
83. Fu Z, Smith PC, Zhang L, et al. Effects of raf kinase inhibitor protein expression on suppression of prostate cancer metastasis. JNatl Cancer Inst 2003;95:878-89.
84. Lee EC, Frolov A, Li R, et al. Targeting Aurora kinases for the treatment of prostate cancer. Cancer Res 2006;66: 4996-5002.
85. Tsui KH, Chung LC, Feng TH, et al. Upregulation of prostate- derived Ets factor by luteolin causes inhibition of cell proliferation and cell invasion in prostate carcinoma cells. IntJCancer 2012;130:2812-23.
86. Liong ML, Lim CR, Yang H, et al. Blood-based biomarkers of aggressive prostate cancer. PLoS One 2012;7:e45802.
87. Du Pasquier L. Innate immunity in early chordates and the appearance of adaptive immunity. C R Biol 2004;327: 591-601.
88. Yeh JH, Sidhu SS, Chan AC. Regulation of a late phase of T cell polarity and effector functions by Crtam. Cell 2008; 132:846-59.
89. Roth C, Schuierer M, Gunther K, et al. Genomic structure and DNA binding properties of the human zinc finger transcriptional repressor AP-2rep (KLF12). Genomics 2000;63: 384-90.
90. Foster KW, Frost AR, McKie-Bell P, et al. Increase of GKLF messenger RNA and protein expression during progression of breast cancer. Cancer Res 2000;60:6488-95.
91. Foster KW, Ren S, Louro ID, et al. Oncogene expression cloning by retroviral transduction of adenovirus E1Aimmortalized rat kidney RK3E cells: transformation of a host with epithelial features by c-MYC and the zinc finger protein GKLF. CellGrowth Differ 1999;10:423-34.
92. Adam PJ, Regan CP, Hautmann MB, et al. Positive- and negative-acting Kruppel-like transcription factors bind a transforming growth factor beta control element required for expression of the smooth muscle cell differentiation marker SM22alpha in vivo. J Biol Chem 2000;275: 37798-806.
93. Black AR, Black JD, Azizkhan-Clifford J. Sp1 and kruppellike factor family of transcription factors in cell growth regulation and cancer. JCell Physiol 2001;188:143-60.
94. Wu Q, Dhir R, Wells A. Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion. Mol Cancer 2012;11:3.
95. Holcomb IN, Grove DI, Kinnunen M, et al. Genomic alterations indicate tumor origin and varied metastatic potential of disseminated cells from prostate cancer patients. Cancer Res 2008;68:5599-608.
96. Attard G, Swennenhuis JF, Olmos D, et al. Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer. Cancer Res 2009;69:2912-8.
97. Olmos D, Arkenau HT, Ang JE, et al. Circulating tumour cell (CTC) counts as intermediate end points in castrationresistant prostate cancer (CRPC): a single-centre experience. Ann Oncol 2009;20:27-33.
98. Leversha MA, Han J, Asgari Z, et al. Fluorescence in situ hybridization analysis of circulating tumor cells in metastatic prostate cancer. Clin Cancer Res 2009;15:2091-7.
99. Nagrath S, Sequist LV, Maheswaran S, et al. Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature 2007;450:1235-9.
100. Kim P, Liu X, Lee T, et al. Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients. Proteome Sci 2011;9:75.
101. Kim SJ, Masago A, Tamaki Y, etal. A novel approach using telomerase-specific replication-selective adenovirus for detection of circulating tumor cells in breast cancer patients. Breast Cancer ResTreat 2011;128:765-73.
102. Powell AA, Talasaz AH, Zhang H, et al. Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines. PLoS One 2012; 7:e33788.
103. Molloy TJ, Devriese LA, Helgason HH, et al. A multimarker QPCR-based platform for the detection of circulating tumour cells in patients with early-stage breast cancer. BrJ Cancer 2011;104:1913-9.
104. Molloy TJ, Roepman P, Naume B, et al. A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients. PLoS One 2012;7: e32426.
105. Obermayr E, Sanchez-Cabo F, Tea MK, et al. Assessment of a six gene panel for the molecular detection of circulating tumor cells in the blood of female cancer patients. BMCCancer 2010;10:666.
106. Obermayr E, Castillo-Tong DC, Pils D, et al. Molecular characterization of circulating tumor cells in patients with ovarian cancer improves their prognostic significance - A study of the OVCAD consortium. Gynecol Oncol 2013;128: 15-21.
107. Chen CL, Mahalingam D, Osmulski P, et al. Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate 2013;73:813-26.
108. Hsieh AC, Liu Y, Edlind MP, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature 2012;485:55-61.
109. Lu W, Tinsley HN, Keeton A, et al. Suppression of Wnt/ beta-catenin signaling inhibits prostate cancer cell proliferation. EurJ Pharmacol 2009;602:8-14.
110. Chen G, Shukeir N, Potti A, et al. Upregulation of Wnt-1 and beta-catenin production in patients with advanced metastatic prostate carcinoma: potential pathogenetic and prognostic implications. Cancer 2004;101:1345-56.
111. Ohigashi T, Mizuno R, Nakashima J, et al. Inhibition of Wnt signaling downregulates Akt activity and induces chemosensitivity in PTEN-mutated prostate cancer cells. Prostate 2005;62:61-8.
112. Syed Khaja AS, Helczynski L, Edsjo A, et al. Elevated level of Wnt5a protein in localized prostate cancer tissue is associated with better outcome. PLoS One 2011;6:e26539.
113. Yamamoto H, Oue N, Sato A, et al. Wnt5a signaling is involved in the aggressiveness of prostate cancer and expression of metalloproteinase. Oncogene 2010;29:2036-46.
114. Chakraborty G, Jain S, Behera R, et al. The multifaceted roles of osteopontin in cell signaling, tumor progression and angiogenesis. CurrMolMed 2006;6:819-30.
115. Tilli TM, Mello KD, Ferreira LB, et al. Both osteopontin-c and osteopontin-b splicing isoforms exert pro-tumorigenic roles in prostate cancer cells. Prostate 2012;72:1688-99.
116. Chakrabarti R, Robles LD, Gibson J, et al. Profiling of differential expression of messenger RNA in normal, benign, and metastatic prostate cell lines. Cancer Genet Cytogenet 2002;139:115-25.
117. Gill SA, Meier PA, Kendall BS. Use of desmin immunohistochemistry to distinguish between mesothelial cells and carcinoma in serous fluid cell block preparations. ActaCytol 2000;44:976-80.
118. Zheng J, Rudra-Ganguly N, Powell WC, etal. Suppression of prostate carcinoma cell invasion by expression of antisense L-plastin gene. AmJ Pathol 1999;155:115-22.
119. Yu HM, Frank DE, Zhang J, et al. Basal prostate epithelial cells stimulate the migration of prostate cancer cells. Mol Carcinog 2004;41:85-97.
120. Wang L, Liu X, Kreis W, et al. Involvement of prostate specific antigen in the stimulation of LNCaP cell growth. Oncol Rep 1996;3:911-7.
121. Bhattacharyya RS, Stern PH. IGF-I and MAP kinase involvement in the stimulatory effects of LNCaP prostate cancer cell conditioned media on cell proliferation and protein synthesis in MC3T3-E1 osteoblastic cells. J Cell Biochem 2003;90:925-37.
122. Barille S, Collette M, Bataille R, et al. Myeloma cells upregulate interleukin-6 secretion in osteoblastic cells through cell-to-cell contact but downregulate osteocalcin. Blood 1995;86:3151-9.
123. Wang J, Levenson AS, Satcher RL, Jr. Identification of a unique set of genes altered during cell-cell contact in an in vitro model of prostate cancer bone metastasis. IntJMol Med 2006;17:849-56.
124. Zhang S, Wang J, Bilen MA, et al. Modulation of prostate cancer cell gene expression by cell-to-cell contact with bone marrow stromal cells or osteoblasts. Clin Exp Metastasis 2009;26:993-1004.
125. Andreasen PA, Kjoller L, Christensen L, et al. The urokinase- type plasminogen activator system in cancer metastasis: a review. IntJCancer 1997;72:1-22.
126. Pulukuri SM, Gondi CS, Lakka SS, et al. RNA interference- directed knockdown of urokinase plasminogen activator and urokinase plasminogen activator receptor inhibits prostate cancer cell invasion, survival, and tumorigenicity in vivo. J BiolChem 2005;280:36529-40.
127. Margheri F, D'Alessio S, Serrati S, et al. Effects of blocking urokinase receptor signaling by antisense oligonucleotides in a mouse model of experimental prostate cancer bone metastases. GeneTher 2005;12:702-14.
128. Hart CA, Scott LJ, Bagley S, et al. Role of proteolytic enzymes in human prostate bone metastasis formation: in vivo and in vitro studies. BrJCancer 2002;86:1136-42.
129. Angelucci A, Gravina GL, Rucci N, et al. Suppression of EGF-R signaling reduces the incidence of prostate cancer metastasis in nude mice. Endocr Relat Cancer 2006;13: 197-210.
130. Cozzi PJ, Wang J, Delprado W, et al. Evaluation of urokinase plasminogen activator and its receptor in different grades of human prostate cancer. Hum Pathol 2006;37: 1442-51.
131. Wang G, Haile S, Comuzzi B, et al. Osteoblast-derived factors induce an expression signature that identifies prostate cancer metastasis and hormonal progression. Cancer Res 2009;69:3433-42.
132. Kishi H, Igawa M, Kikuno N, et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. JUrol 2004;171:1855-60.
133. Syed V, Mak P, Du C, et al. Beta-catenin mediates alteration in cell proliferation, motility and invasion of prostate cancer cells by differential expression of E-cadherin and protein kinase D1. JCell Biochem 2008;104:82-95.
134. Viticchie G, Lena AM, Latina A, et al. MiR-203 controls proliferation, migration and invasive potential of prostate cancer cell lines. Cell Cycle 2011;10:1121-31.
135. Shiirevnyamba A, Takahashi T, Shan H, et al. Enhancement of osteoclastogenic activity in osteolytic prostate cancer cells by physical contact with osteoblasts. BrJCancer 2011;104:505-13.
136. Richardsen E, Uglehus RD, Due J, et al. COX-2 is overexpressed in primary prostate cancer with metastatic potential and may predict survival. A comparison study between COX-2, TGF-beta, IL-10 and Ki67. Cancer Epidemiol 2010;34:316-22.
137. Ohshiba T, Miyaura C, Ito A. Role of prostaglandin E produced by osteoblasts in osteolysis due to bone metastasis. Biochem Biophys Res Commun 2003;300:957-64.
138. Ding Q, Bai YF, Wang YQ, et al. TGF-beta1 reverses inhibition of COX-2 with NS398 and increases invasion in prostate cancer cells. AmJMed Sci 2010;339:425-32.
139. Roodman GD. Regulation of osteoclast differentiation. AnnNYAcad Sci 2006;1068:100-9.
140. Liu XH, Kirschenbaum A, Yao S, et al. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/receptor activator of nuclear factor- {kappa}B (RANK) ligand/RANK system. Endocrinology 2005;146:1991-8.
141. Tan D, Wu X, Hou M, et al. Interleukin-6 polymorphism is associated with more aggressive prostate cancer. J Urol 2005;174:753-6.
142. Morrissey C, Lai JS, Brown LG, et al. The expression of osteoclastogenesis-associated factors and osteoblast response to osteolytic prostate cancer cells. Prostate 2010;70:412-24.
143. Tsui KH, Chang YL, Feng TH, et al. Growth differentiation factor-15 upregulates interleukin-6 to promote tumorigenesis of prostate carcinoma PC-3 cells. J Mol Endocrinol 2012;49:153-63.
144. Jacob K, Webber M, Benayahu D, et al. Osteonectin promotes prostate cancer cell migration and invasion: a possible mechanism for metastasis to bone. CancerRes 1999;59: 4453-7.
145. Said NA, Najwer I, Socha MJ, et al. SPARC inhibits LPAmediated mesothelial-ovarian cancer cell crosstalk. Neoplasia 2007;9:23-35.
146. Lin DL, Tarnowski CP, Zhang J, et al. Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. Prostate 2001;47:212-21.
147. Fujita T, Shiba H, Sakata M, et al. SPARC stimulates the synthesis of OPG/OCIF, MMP-2 and DNA in human periodontal ligament cells. J Oral Pathol Med 2002;31: 345-52.
148. Arias CR, Yeh HY, Soo VW. Biomarker identification for prostate cancer and lymph node metastasis from microarray data and protein interaction network using gene prioritization method. ScientificWorld J 2012;2012:842727.
149. Chen M, Wang K, Zhang L, et al. The discovery of putative urine markers for the specific detection of prostate tumor by integrative mining of public genomic profiles. PLoS One 2011;6:e28552.
150. Baetke SC, Adriaens ME, Seigneuric R, et al. Molecular pathways involved in prostate carcinogenesis: insights from public microarray datasets. PLoS One 2012; 7:e49831.
151. Steinberg J, Oyasu R, Lang S, et al. Intracellular levels of SGP-2 (Clusterin) correlate with tumor grade in prostate cancer. ClinCancer Res 1997;3:1707-11.
152. Miyake H, Muramaki M, Furukawa J, et al. Serum level of clusterin and its density in men with prostate cancer as novel biomarkers reflecting disease extension. Urology 2010;75:454-9.
153. Agarwal N, Sonpavde G, Sternberg CN. Novel molecular targets for the therapy of castration-resistant prostate cancer. EurUrol 2012;61:950-60.
154. Lenferink AE, Cantin C, Nantel A, et al. Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies. Oncogene 2010;29:831-44.
155. Shiota M, Zardan A, Takeuchi A, et al. Clusterin mediates TGF-beta-induced epithelial-mesenchymal transition and metastasis via Twist1 in prostate cancer cells. Cancer Res 2012;72:5261-72.
156. Tsui KH, Chang PL, Feng TH, et al. Evaluating the function of matriptase and N-acetylglucosaminyltransferase V in prostate cancer metastasis. Anticancer Res 2008;28: 1993-9.
157. Balan V, Nangia-Makker P, Kho DH, etal. Tyrosine-phosphorylated galectin-3 protein is resistant to prostate-specific antigen (PSA) cleavage. J Biol Chem 2012;287:5192-8.
158. Wang Y, Balan V, Kho D, et al. Galectin-3 regulates p21 stability in human prostate cancer cells. Oncogene 2012. doi:10.1038/onc.2012.528.
159. Glinskii OV, Sud S, Mossine VV, et al. Inhibition of prostate cancer bone metastasis by synthetic TF antigen mimic/ galectin-3 inhibitor lactulose-L-leucine. Neoplasia 2012;14: 65-73.
160. Oh J, Takahashi R, Kondo S, et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001;107: 789-800.
161. Clark JC, Thomas DM, Choong PF, et al. RECK-a newly discovered inhibitor of metastasis with prognostic significance in multiple forms of cancer. Cancer Metastasis Rev 2007;26:675-83.
162. Rabien A, Ergun B, Erbersdobler A, et al. RECK overexpression decreases invasive potential in prostate cancer cells. Prostate 2012;72:948-54.
163. Srinivasan S, Patil AH, Verma M, et al. Genome-wide Profiling of RNA splicing in prostate tumor from RNAseq data using virtual microarrays. JClinBioinforma 2012;2:21.
164. Tomlins SA, Rhodes DR, Yu J, et al. The role of SPINK1 in ETS rearrangement-negative prostate cancers. Cancer Cell 2008;13:519-28.
165. Barbieri CE, Baca SC, Lawrence MS, et al. Exome sequencing identifies recurrent SPOP, FOXA1, and MED12 mutations in prostate cancer. Nat Genet 2012;44:685-9.